These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 38668528)

  • 1. Knowledge and Attitudes Regarding the Vaccination of Brazilian Immigrants in Portugal: Risks When Returning to Their Country of Origin?
    Freitas IP; Igreja RP; Pacheco MR; Teodósio R
    Trop Med Infect Dis; 2024 Mar; 9(4):. PubMed ID: 38668528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Yellow Fever prevention strategies awareness among HIV-infected patients in São Paulo, Brazil.
    Avelino-Silva VI; Francelino HS; Kallás EG
    Rev Inst Med Trop Sao Paulo; 2014; 56(5):417-20. PubMed ID: 25229222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knowledge, Attitude, and Practice of Jinka University Students About Yellow Fever, Ethiopia: A Cross-Sectional Study.
    Endale A; Medhin G; Hilo AA; Abegaz WE; Legesse M
    Risk Manag Healthc Policy; 2020; 13():1225-1236. PubMed ID: 32884383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidemiological monitoring of the last outbreak of yellow fever in Brazil - An outlook from Portugal.
    Selemane I
    Travel Med Infect Dis; 2019; 28():46-51. PubMed ID: 30583006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compliance with yellow fever and measles vaccines in the revaccination program post-hematopoietic cell transplantation.
    de Almeida Testa LH; Simione AJ; Dos Santos ACF; Colturato I; Barbieri F; de Souza MP; Colturato VR; Machado CM
    Transpl Infect Dis; 2023 Aug; 25(4):e14098. PubMed ID: 37428874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community knowledge, attitudes and practices on Yellow fever in South Omo area, Southern Ethiopia.
    Legesse M; Endale A; Erku W; Tilahun G; Medhin G
    PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006409. PubMed ID: 29630594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of travel medicine practice by yellow fever vaccination centers in England, Wales, and Northern Ireland.
    Boddington NL; Simons H; Launders N; Gawthrop M; Stillwell A; Wong C; Mathewson J; Hill DR
    J Travel Med; 2012; 19(2):84-91. PubMed ID: 22414032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brazilian recommendations on the safety and effectiveness of the yellow fever vaccination in patients with chronic immune-mediated inflammatory diseases.
    Pileggi GS; Da Mota LMH; Kakehasi AM; De Souza AW; Rocha A; de Melo AKG; da Fonte CAM; Bortoletto C; Brenol CV; Marques CDL; Zaltman C; Borba EF; Reis ER; Freire EAM; Klumb EM; Christopoulos GB; Laurindo IMM; Ballalai I; Da Costa IP; Michelin L; de Azevêdo Valadares LD; Chebli LA; Lacerda M; Toscano MAF; Yazbek MA; De Abreu Vieira RMR; Magalhães R; Kfouri R; Richtmann R; Merenlender SDCS; Valim V; De Assis MR; Kowalski SC; Trevisani VFM
    Adv Rheumatol; 2019 Apr; 59(1):17. PubMed ID: 31036077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preferences and decision needs of Boston-area travelers to countries with risk of Yellow fever virus transmission: implications for health care providers.
    Lown BA; Chen LH; Han PV; Jentes ES; Wilson ME; Benoit CM; Avery KA; Ooi W; Hamer DH; Barnett ED;
    J Travel Med; 2014; 21(4):266-71. PubMed ID: 24734961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active assessment of adverse events following yellow fever vaccination of persons aged 60 years and more.
    Miyaji KT; Luiz AM; Lara AN; do Socorro Souza Chaves T; Piorelli Rde O; Lopes MH; Sartori AM
    Hum Vaccin Immunother; 2013 Feb; 9(2):277-82. PubMed ID: 23291944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Booster dose after 10 years is recommended following 17DD-YF primary vaccination.
    Campi-Azevedo AC; Costa-Pereira C; Antonelli LR; Fonseca CT; Teixeira-Carvalho A; Villela-Rezende G; Santos RA; Batista MA; Campos FM; Pacheco-Porto L; Melo Júnior OA; Hossell DM; Coelho-dos-Reis JG; Peruhype-Magalhães V; Costa-Silva MF; de Oliveira JG; Farias RH; Noronha TG; Lemos JA; von Doellinger Vdos R; Simões M; de Souza MM; Malaquias LC; Persi HR; Pereira JM; Martins JA; Dornelas-Ribeiro M; Vinhas Ade A; Alves TR; Maia Mde L; Freire Mda S; Martins Rde M; Homma A; Romano AP; Domingues CM; Tauil PL; Vasconcelos PF; Rios M; Caldas IR; Camacho LA; Martins-Filho OA
    Hum Vaccin Immunother; 2016; 12(2):491-502. PubMed ID: 26360663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Knowledge, attitude, and practices regarding human papilloma virus vaccination among physicians in Qatar.
    Albayat SS; Mundodan JM; Elmardi K; Hasnain S; Khogali H; Baaboura R; Al-Romaihi HE; AlKubaisi NJ; Bougmiza MI
    Womens Health (Lond); 2024; 20():17455057241227360. PubMed ID: 38282514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Review of the risks and benefits of yellow fever vaccination including some new analyses.
    Monath TP
    Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seroconversion and antibody persistence after yellow fever vaccination in people living with HIV: impact of baseline HIV viral load and yellow fever seropositivity.
    Martin C; Florence E; Domingo C; Delforge M; De Wit S; Dauby N
    J Travel Med; 2022 Dec; 29(8):. PubMed ID: 35285913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yellow fever vaccination coverage among children in Brazilian capitals.
    Veras MA; Flannery B; de Moraes JC; da Silva Teixeira AM; Luna EJ;
    Vaccine; 2010 Sep; 28(39):6478-82. PubMed ID: 20674878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse events following yellow fever vaccination in immunocompromised persons.
    Lara AN; Miyaji KT; Ibrahim KY; Lopes MH; Sartori AMC
    Rev Inst Med Trop Sao Paulo; 2021; 63():e13. PubMed ID: 33656136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Staples JE; Gershman M; Fischer M;
    MMWR Recomm Rep; 2010 Jul; 59(RR-7):1-27. PubMed ID: 20671663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of adverse events after yellow fever vaccination between elderly and non-elderly travellers: questionnaire survey in Japan over a 1-year period.
    Tanizaki R; Ujiie M; Hori N; Kanagawa S; Kutsuna S; Takeshita N; Hayakawa K; Kato Y; Ohmagari N
    J Travel Med; 2016 Mar; 23(3):. PubMed ID: 27021495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sanger-based sequencing technology for yellow fever vaccine genetic quality control.
    Pestana CP; Lawson-Ferreira R; Lessa-Aquino C; Leal MDLF; Freire MDS; Homma A; Medeiros MA
    J Virol Methods; 2018 Oct; 260():82-87. PubMed ID: 30009851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serological Protection 5-6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes.
    Idoko OT; Domingo C; Tapia MD; Sow SO; Geldmacher C; Saathoff E; Kampmann B
    Front Immunol; 2020; 11():577751. PubMed ID: 33133096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.